Skip to main content

Table 2 Univariate analysis for overall survival

From: Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer

 

Univariate analysis

Multivariate analysis

HR

95% CI

P

HR

95% CI

P

Age (years)

< 58 years

1

  

0.913

    

≥58 years

1.03

0.57

1.86

     

Sex

Male

1

  

0.831

    

Female

0.94

0.51

1.73

     

Disease presentation

Recurrent

1

  

0.327

    

Metastatic

1.42

0.70

2.89

     

Differentiation

WD

1

  

0.602

    

MD

4.94

0.61

39.76

     

PD

4.41

0.59

32.82

     

SRC

3.41

0.44

26.72

     

Others*

3.64

0.38

35.20

     

HER2

Negative

1

  

0.892

    

Positive

0.81

0.34

1.93

     

Palliative chemotherapy history

No

1

  

0.003

1

  

0.005

Yes

4.19

1.63

10.78

 

10.78

2.05

56.81

 

Molecular subtype of primary tumor

MSI

0.87

0.11

6.64

0.143

    

EBV

19.11

1.90

192.25

     

CIN-like

1.01

0.49

2.07

     

GS-like

1

       

Unknown

1.33

0.63

2.84

     

VEGF-A (pg/mL)

< 100.9 pg/mL

1

  

0.127

    

≥100.9 pg/mL

1.58

0.88

2.86

     

IL-10 (pg/mL)

> 243.8 pg/mL

1

  

0.16

    

≥243.8 pg/mL

1.64

0.82

3.25

     

TGF-β1 (pg/mL)

< 393.6 pg/mL

1

  

0.197

    

≥393.6 pg/mL

1.97

0.70

5.55

     

Cytokine-scoring model

0–1

1

  

0.037

    

(number of high level of cytokines)

2–3

1.91

1.04

3.49

     

CD4/CD3 (%)

< 41.7%

1

  

0.232

    

≥41.7%

0.65

0.32

1.32

     

CD8/CD3 (%)

< 33.3%

1

  

0.272

    

≥33.3%

1.58

0.70

3.57

     

CD4/CD8 ratio

< 0.6

1

  

0.034

    

≥0.6

0.35

0.13

0.92

     

CD8CD45RO+/CD8 (%)

< 67.2%

1

  

0.021

1

  

0.019

≥67.2%

2.54

1.15

5.59

 

3.25

1.22

8.68

 

CD8CD25+/CD8 (%)

< 1.6%

1

  

0.081

    

≥1.6%

1.92

0.92

3.99

     

CD8CD69+/CD8 (%)

< 28.0%

1

  

0.054

    

≥28.0%

2.09

0.99

4.41

     

CD8HLA-DR+/CD8 (%)

< 28.4%

1

  

0.008

1

  

0.012

≥28.4%

3.77

1.43

9.96

 

5.36

1.45

19.88

 

CD8 TIM3+/CD8 (%)

< 0.2%

1

  

0.082

    

≥0.2%

0.50

0.23

1.09

     

CD8 LAG3+/CD8 (%)

< 3.7%

1

  

0.098

    

≥3.7%

1.92

0.89

4.17

     

CD8 PD1+/CD8 (%)

< 50.2%

1

  

0.038

    

≥50.2%

2.58

1.06

6.31

     

CD3 PD1+/CD3 (%)

< 17.2%

1

  

0.001

1

  

< 0.001

≥17.2%

3.53

1.66

7.52

 

8.61

2.81

26.37

 

CD4 PD1+/CD4 (%)

< 32.1%

1

  

0.052

    

≥32.1%

2.11

0.99

4.50

     

FoxP3+ Tregs (No)

< 380

1

  

0.029

1

  

0.001

≥380

0.40

0.18

0.91

 

0.13

0.04

0.42

 

PD-L1 positive tumor cells (%)

< 1%

1

  

0.87

    

≥1%

1.07

0.49

2.34

     
  1. VEGF vascular endothelial growth factor, IL interleukin, TGF-β1 transforming growth factor- beta1, CD cluster of differentiation, WD well differentiated, MD moderate differentiated, PD poorly differentiated, SRC signet ring cell carcinoma, MSI microsatellite instability, EBV Epstein-Barr virus, CIN chromosomal instability, GS genomically stable, HR hazard ratio, CI confidence interval, P p-value, No number
  2. Others*: mucinous adenocarcinoma, undifferentiated carcinoma
Back to article page